AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical product, comprising a pharmaceutical aqueous preparation containing at least one member selected from the group consisting of tranilast and a salt thereof in a packaging container through which the contents are visible and which blocks light in the wavelength range from 365 nm to 430 nm.

2. (Original) A pharmaceutical product according to Claim 1, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm.

3. (Original) A pharmaceutical product according to Claim 2, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 350 nm to 430 nm.

4. (Original) A pharmaceutical product according to Claim 2, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 350 nm to 450 nm.

5. (Previously Presented) A pharmaceutical product according to Claim 1, wherein the packaging container has an average light transmittance of 20% or lower in the wavelength range from 365 nm to 430 nm, 20% or lower in the wavelength range from 350 nm to 430 nm, and 20% or lower in the wavelength range from 350 nm to 450 nm.

6. (Original) A pharmaceutical product according to Claim 1, wherein the packaging container has an average light transmittance of 30% or higher in the wavelength range from 455 nm to 780 nm.

7. (Currently Amended) A pharmaceutical product according to Claim 1, wherein the pharmaceutical preparation further comprises at least one member selected from the group consisting of berberine, berberine, tannate, berberine chloride, berberine sulfate, ~~B2 vitamins,~~ flavin adenine dinucleotide, flavin mononucleotide, riboflavin, riboflavin phosphate, riboflavin acetate, riboflavin butyrate, hesperidin, methyl hesperidin, oxyquinoline, oxyquinoline sulfate, oxyquinoline phosphate, ~~B2 vitamins,~~ cyanocobalamin, mecobalamin, cobamamide, hydroxocobalamin, ~~derivatives thereof,~~ and salts thereof.

8. (Cancel)

9. (Original) A pharmaceutical product according to Claim 8, wherein tranilast and a salt thereof is present in a total proportion of 0.01 to 20% by weight based on the total amount of the pharmaceutical preparation.

10. (Currently Amended) A pharmaceutical product according to Claim 1, wherein the pharmaceutical aqueous preparation is an eye drop, eye wash, injection, externally applied skin medicine, nasal drop, or contact lens-care formulation.

11. (Currently Amended) A method for inhibiting photodegradation of tranilast or a salt thereof, comprising placing a pharmaceutical aqueous preparation comprising at least one member selected from the group consisting of tranilast and a salt thereof in a packaging container through which the contents are visible and which blocks light in the wavelength range from 365 nm and 430 nm.

12. (Cancel)

13. (Cancel)